Novel Broad-Spectrum Flavivirus Inhibitors

At a Glance

Researchers at Colorado State University in collaboration with the University of Northern Colorado have developed a new antiviral therapeutics for treatment of mosquito-borne flavivirus infection, which includes Dengue, West Nile and Yellow Fever.

The novel broad-spectrum anti-flaviviral target was created using a high throughput screening protocol to identify a series of small molecule inhibitory candidates.  These inhibitory compounds, as described in a recent Journal of Virology publication, target the enzyme that is responsible for capping the RNA viral genome.  In vitro studies indicate the compounds demonstrate good specificity and low toxicity.

For more information, please contact our office!

Background

Arthropod-borne virus infections remain a major cause of morbidity and mortality worldwide. More than two billion people are at risk of infection with dengue virus (DEN) and 600 million people at risk of infection with yellow fever virus (YF) (20). Globally, an estimated 50-100 million cases of DEN and 200,000 cases of YF are reported each year, which infections result in approximately 20,000 (DEN) and 30,000 (YF) deaths annually (11). There are currently no clinically useable chemotherapeutic options for the treatment of any flavivirus infection, making it essential that new strategies and targets for the treatment of flavivirus infections be identified.

Benefits

  • Lead compound demonstrates improved activity over Ribavirin
  • GTP displacement assay allows for high throughput screening of small molecule compounds
  • The RNA capping enzyme is conserved across multiple flaviviruses including dengue, West Nile, and yellow fever viruses
Last Updated: January 2024
Opportunity

Available for Licensing

IP Status

US Utility Patent: US 9206412

Inventors

Brian Geiss
Susan Keenan
Hillary Stahla-Beek

Reference Number
11-010
Licensing Manager

Steve Foster
Steve.Foster@colostate.edu
970-491-7100